Check us out on Facebook
Blackboard
Webmail

Ashim K. Mitra

Ashim K. Mitra, Ph.D.

Chairman, Pharmaceutical Sciences

University of Missouri-Kansas City School of Pharmacy
Division of Pharmaceutical Sciences
HSB 5258
2464 Charlotte St.
Kansas City, MO 64108
Phone: 816-235-1615
Fax: 816-235-5779
E-mail: mitraa@umkc.edu

Biography

Dr. Mitra received his Ph.D. in Pharmaceutical Chemistry in 1983 from the University of Kansas. Upon graduation he was employed as an Assistant Professor of Biopharmaceutics at the University of Nebraska Medical Center for one year. In 1984, he joined Purdue University as an Assistant Professor and later became an Associate Professor of Physical Pharmacy from 1989-1994. That year in 1994, he was accepted as Professor and Chairman of UMKC School of Pharmacy, Division of Pharmaceutical Sciences. He received the University of Missouri Curators’ Professor of Pharmacy Award in 2002. Within two years, he was appointed Co-Director, Kansas City Vision Research Center, UMKC School of Medicine and UMKC Vice Provost for Interdisciplinary Research.

Research Interests

His current research interests are focused on two main areas: delivery and targeting of antiviral agents and development of noninvasive delivery systems for peptide and protein drugs.

» Curriculum Vitae

Recent Awards and Honors:

April 2010
Ranked #3rd Author in the World in the Prodrug Arena’, (http://www.biomedexperts.com/start/PersonDetailpage.aspx?pid=949912)

Ranked #5th on the list of ‘Top Ten Researchers” in the world by Pharmaceutical Research - official Journal of America Association of Pharmaceutical Scientist (AAPS) http://www.springerlink.com/content/105282/

In 2007, Dr. Mitra became the Recipient of the ARVO/Pfizer Ophthalmics Translational Research Award. The ARVO/Pfizer Award honors excellence in areas of research and fundamental scientific discoveries, concepts and novel technologies, leading to clinical evidence of diagnosis, prevention, or amelioration of the pathological eye and/or an understanding of the normal vision processes.

Dr. Mitra is the recipient of a numbers of research awards from the National Institutes of Health, the American Association of Pharmaceutical Scientists, the American Association of Colleges of Pharmacy, and numerous pharmaceutical organizations. He served as a regular member of the National Institute of Health (NIH) Pharmacology & Toxicology Study Section. Currently, he is serving on the newly formed NIH Gene and Drug Delivery Study Section.

  • PATENTS
    United States Patent and Trademark Office
    US Patent Issued: # US 7,214,664
    Patent Issue Date: May 8, 2007
    Patent Title: “Peptidyl Prodrugs That Resist P-Glycoprotein Mediated Drug Efflux”

    United States Patent and Trademark Office
    US Patent Issued: # US 2009/0092665 A1
    Patent Issue Date: April 9, 2009
    Patent Title: “Ophthalmic Compositions Comprising Calcineurin Inhibitors or Mtor Inhibitors”

    United States Patent and Trademark Office
    US Patent Issued: # US 7,553,812 B2
    Patent Issue Date: June 30, 2009
    Patent Title: “Acyclovir-Peptide Analogs”

GRANT AWARDS:

Ashim K. Mitra, Ph.D., has received more than $5.5 million in grant money from the National Institutes of Health (NIH) to continue work on three separate studies.

Current Funding
1. Co-Investigator, 1 R01 EY020916-01A1, “Suppression of Ocular Scarring–Controlled Delivery of an ALK-5 Inhibitor”, $310,500, 09/01/2011-08/31/2014.

2. Principal Investigator, 2 R01 EY010659-12A2, “Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Edema”, $1,862,500, 04/01/1996-03/31/2013.

3. Principal Investigator, 1 R01 AI071199-01-A2 “Protease Inhibitor Analogues for Enhanced Transport Across Blood-Brain Interfaces”, $1,862.500, 04/01/2007 – 03/31/2012.

4. Principal Investigator, 5 R01 EY009171-13 (Revised) “Ocular Disposition of Antimicrobial Agents” $12,025,000, 11/01/1994 – 12/31/2012.

Recent Publications (Selected from over 200):

  • 1. Sudharshan Hariharan, Nilay R. Thakkar, Ashim K. Mitra, Transporter-Targeted Drug Delivery to the Retina, Retina Today (Drug Delivery to the Posterior Segment), May/June, 4 (4):57-62, 2009.
  • 2. Mitra AK. Role of Transporters in Ocular Drug Delivery System, Pharm Res, 26(5):1192-1196, 2009.
  • 3. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent Perspectives in Ocular Drug Delivery. Pharm Res 26(5):1197-1216, 2009.
  • 4. Karla P; Quinn TL; Henderdon BL; Thomas P; Pal D; Mitra AK. Expression of Multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. JOPT 25(2), J. Ocular Pharmacol & Therap, 25(2):121-132, 2009.
  • 5. Hariharan S; Gunda S; Mishra GP; Pal D; Mitra AK. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroid. Pharm Res, 26(5):1270-1282, 2009.
  • 6. Janoria KG; Boddu, Sai HS; Wang Z; Paturi DK; Samanta S; Pal D; Mitra AK. Vitreal Pharmacokinetics of Biotinylated Ganciclovir: Role of Sodium-Dependent Multivitamin Transporter Expressed on Retina, J. Ocular Pharmacol & Therap, 25(1):39-49, 2009.
  • 7. Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra AK. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells, Curr Eye Res, 34:1-9, 2009.
  • 8. Katragadda S; Jain R; Kwatra D; Hariharan S; Mitra AK. Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: Interaction with the transporters of Caco-2- cells, Int. J. Pharm., 362(1-2):93-101 2008.
  • 9. Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK. Interaction of Dipeptide Prodrugs of Saquinavir with Multidrug Resistance Protein-2 (MRP-2): Evasion of MRP-2 Mediated Efflux, Int. J Pharm., 362(1-2):44-51. 2008
  • 10. Talluri RS; Samanta SK; Gaudana R; Mitra AK. Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir, Int. J. Pharm., 361:118-124, 2008.
  • 11. Boddu SHS; Jwala J; Janoria D; Pal D; Mitra AK. Development of Steroid-Nanoparticles for the Treatment of Macular Edema, JIDR J. Interdis Res, 2(1):81-99, 2008.
  • 12. Agarwal S; Boddu SHS; Jain R; Samanta S; Pal D; Mitra AK. Peptide prodrugs: Improved oral absorption of Lopinavir, a HIV protease inhibitor, Int. J. Pharm/Sci Dir., 359, 7-14, 2008.
  • 13. Luo S; Wang Z; Kansara V; Pal D; Mitra AK. Activity of a sodium-dependent Vitamin C transporter (SVCT) in MDCK-MDR1 cells and mechanism of ascorbate uptake, Int. J. Pharm., 358:168-176, 2008.
  • 14. Katragadda S; Gunda S; Hariharan S; Mitra AK. Ocular pharmacokinetics of Acyclovir amino acid ester prodrugs in the anterior chamber: Evaluation of their utility in treating ocular HSV infections, Int J. Pharm, Int. J. Pharm/Science Direct, 359:15-24, 2008.
  • 15. Kansara V; Paturi D; Luo S, Gaudana, R; Mitra AK. Folic Acid Transport via High Affinity Carrier-Mediated System in Human Retinoblatoma Cells, Int. J. Pharm/Sci Dir, 355:1-2, 210-219, 2008.
  • 16. Atluri H; Talluri RS; Mitra AK. Functional Activity of a Large Neutral Amino Acid Transporter (LAT) in Rabbit Retina: A Study Involving the in vivo Retinal Uptake and Vitreal Pharmacokinetics of L-phenyl Alamine, Int. J. Pharm., 347:1-2, 23-30, 2008.
  • 17. Jain R; Duvvuri S, Kansara V, Mandava NK, Mitra AK, Intestinal Absorption of novel-dipeptide prodrugs of a saquinavir in rats, .Int. J. Pharm/Sci Dir, 336, 233-240, 2007.
  • 18. Agarwal S; Pal D; Mitra AK. Both P-gp and MRP2 Mediate Transport of Lopinavir, A Protease Inhibitor, ScienceDirect, Int J. Pharm., 339(1-2):139-147, 2007.
  • 19. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int. J. Pharm. 338(1-2):21-26, 2007.
  • 20. Denora N; Laquintana V; Lopedota A; Serra M; Dazzi L; Biggio G; Pal D; Mitra AK, Latrofa A; Trapani G; Liso G. Novel L- Dopa and Dopamine Prodrugs Containing a 2-Phenyl-imidazopyridine Moiety. Pharm. Res. 24(7):1309-1324, 2007.
  • 21. Chittchang M, Mitra AK, Johnston TP. Interplay of Secondary Structure and Charge on the Diffusion of a Polypeptide through Negatively Charged Aqueous Pores. Pharm. Res. 24(3):502-511, 2007.
  • 22. Kansara V; Hao Y; Mitra AK. Dipetide Monoester Ganciclovir Prodrugs for Trans-scleral Drug Delivery: Targeting the Oligopeptide Transporter on Rabbit Retina, J. Ocul Pharmacol. & Therap, 23(4):321-334, 2007.
  • 23. Janoria KG; Gunda S; Boddu SHS; Mitra AK. Novel Approaches to Retinal Drug Delivery, Expert Opinion in Drug Delivery, 4(4):371-388, 2007.
  • 24. Janoria KG, Hariharan S, Dasari CR, Mitra AK. Recent Patents and Advances in Ophthalmic Drug Delivery. Recent Patents on Drug Delivery & Formulation, Vol. 1, No 2, 161-170, 2007.
  • 25. Janoria KG; Mitra AK. Effect of Lactide/Glycolide Ratio on the In Vitro Release of Ganciclovir and its Lipophilic Prodrug (GCV - Monobutyrate) from PLGA Microspheres. Int. J. Pharm/ScienceDirect, 338(1-2):133-141, 2007.
  • 26. Duvvuri S; Janoria K; Pal; Mitra AK. Controlled delivery of ganciclovir to the retina with drug loaded PLGA microspheres dispersed in PLGA-PEG-PLGA gel: A novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J Ocul Pharmacol Ther., 23(3):264-274, 2007.
  • 27. Pal D; Mitra AK. CYP3A4 and MDR Mediated Interactions in Drug Therapy, Informa HealthCare, Clin Res & Reg Affairs, 23(3):125-163, 2007.
  • 28. Karla PK, Pal D, Quinn T. Mitra AK. Molecular Evidence and Functional Expression of a Novel Drug Efflux Pump (ABCC2) in Human Corneal Epithelium and Rabbit Cornea and its Role in Ocular Drug Efflux. Int. J. Pharm., 336(1):12-21, 2007.
  • 29. Karla PK, Pal D, Mitra AK. Molecular Evidence and Functional Expression of Multidrug Resistance Associated Protein (MRP) in Rabbit Corneal Epithelial Cells, Exp. Eye Res., 84(1):53-60, 2007.
  • 30. Kaur IP, Mitra AK, Aggarwal D. Development of a vesicular system for effective ocular delivery of acetazolamide. A comprehensive approach and successful venture. J. Drug Del. Sci. Tech., 17 (1), 33-41, 2007.
  • 31. Agarwal S, Jain R, Pal D, Mitra AK. Functional Characterization of Peptide Transporters in MDCKII-MDR1 Cell Line as a Model for Oral Absorption Studies, Int J Pharm, ScienceDirect 332:147-152, 2007.
  • 32. Pal D; Mitra AK. CYP3A4 and MDR Mediated Interactions in Drug Therapy, Informa HealthCare, Clin Res & Reg Affairs, 23(3):125-163, 2007.
Book Chapters
  • 1. Boddu, S HS; Jwala J; Janoria KG Pal D; Mitra AK. “Development of Steroid-Nanoparticles for the Treatment of Macular Edema”, The Journal of Interdisciplinary Research (JIDR) Vol 2, No 1, Megan Cornell (Ed), KCMO, 81-99, 2008.
  • 2. Karla PK; Kwatra D; Gaudana R; Mitra AK. “Nasal Drug Delivery”, Modified-Release Drug Delivery Technology, 2nd Ed, Vol 2, Michael J. Rathbone, Jonathan Hadgraft, Michael s. Roberts and Majella E. Lane (Eds.), Informa Healthcare, 427-450, 2008.
  • 3. Talluri S; Mishra GP; Mitra AK. Ophthalmic infections and therapeutic strategies, Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, Skinner M, Williams III RO, Taft DR, McConville JT (Eds.), CRC Press, Inc., Florida, 143-170, 2008.
  • 4. Gunda S; Hariharan S; Mandava N; Mitra AK. “Barriers in Ocular Drug Delivery, in: Ocular Transporters” Ophthalmic Diseases and Drug Delivery, Tombran-Tink J, Barnstable CJ (Eds.), Humana Press, Inc., New Jersey, 399-414, 2008.
  • 5. Budda B; Kansara V; Mitra AK. Mechanisms of Drug Entry into Nucleus, Drug Delivery Research Advances, Boris O. Mashkevich (Ed), Nova Science Publishers, Inc., Waltham, MA, Chapter 5, 153-180, 2007.
  • 6. Kansara V; Budda B; Mitra AK. Advancements in Ocular Drug Delivery, Drug Delivery Research Advances, Boris O. Mashkevich (Ed), Nova Science Publishers, Inc., Waltham, MA, Chapter 1, 1-37, 2007.